VK2735

Mechanism of action

Balanced agonism at GLP-1 and GIP receptors — mechanistically the same class as tirzepatide, but a distinct molecule. GLP-1 agonism provides glucose-dependent insulin secretion, glucagon suppression, delayed gastric emptying, and central appetite suppression; GIP agonism adds an independent insulinotropic component and appears to modulate lipid handling and nausea tolerability.

Primary uses

• Obesity (Phase 2)
• Type 2 diabetes mellitus (Phase 2)

Typical dosing

Educational information, not medical advice. The doses on this page come from approved labels, published studies and, where no study exists, amounts reported by users. None is a recommendation for you. An unapproved compound has no established safe or effective human dose, and products sold for “research use only” are not made or tested for people. Talk to a doctor before acting on anything on this site, including before you start, stop or change any medicine or dose. Full medical disclaimer.

Regulatory status

Not approved. Phase 2 VENTURE (SC) reported February 2024; Phase 2 oral tablet study initiated late 2024. Phase 3 planning disclosed in 2024–2025 corporate updates.

Status as of this entry's last review, October 4, 2026. Approvals, compounding rules and sport rules change; the regulatory tracker is checked more often.

What we checked

VK2735 is Viking Therapeutics' GLP-1/GIP dual agonist. One paper indexed on PubMed reports its phase 2 obesity trial. This section records what can be checked.

Identity, computed

Its structure has not been published in a source we could find, so no formula or mass is given.

Regulatory status, read October 5, 2026

Drugs@FDA: 0 records for “VK2735”. EMA medicines list: 0 records for “VK2735”. Run for semaglutide, the same queries return 6 and 5 records (and the registry search 84 trials), so a zero here is an absence, not a broken search. Not named on the WADA 2026 and 2027 Prohibited Lists. As a substance with no current approval for human therapeutic use, it falls under section S0 (non-approved substances), which is prohibited at all times; the lists were read on September 27, 2026.

What the maker or sellers claim

Claim, from Viking Therapeutics: VK2735 is being developed as a weekly injection and as a daily tablet. Results for the tablet were not in the indexed literature on the search date.

The phase 2 trial

VENTURE randomised adults with obesity or overweight plus a weight-related condition, without diabetes, to weekly VK2735 or placebo under the skin for 13 weeks, between August 2023 and February 2024. Mean weight loss ran from 9.2 kg (9.1%) at 2.5 mg to 14.6 kg (14.7%) at 15 mg, against 1.8 kg (1.7%) with placebo, and 93% of treated participants lost at least 5% (Bays et al., 2026). Thirteen weeks is short for an obesity drug; longer phase 3 data will decide where it stands. Trial doses, not doses to use.

What we looked for and did not find

No phase 3 results in the indexed literature as of the search date and no approval anywhere.

References

1. [manufacturer] Viking Therapeutics. Press release: VENTURE Phase 2 positive topline results in obesity, February 2024.
2. [clinicaltrials] ClinicalTrials.gov NCT05930249 (VENTURE, VK2735 SC Phase 2).
3. [manufacturer] Viking Therapeutics corporate update: oral VK2735 Phase 2 initiation, Q4 2024.
4. [clinical-trial] Bays HE, et al. "Weekly Subcutaneous VK2735, a GIP/GLP-1 Receptor Dual Agonist, for Weight Management: Phase 2, Randomized, 13-Week VENTURE Study." Obesity (Silver Spring), 2026;34(3):537-549. PMID: 41508550.

Related peptides

Guides & tools